Filing Details

Accession Number:
0001127602-14-009278
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-28 17:06:52
Reporting Period:
2014-02-26
Filing Date:
2014-02-28
Accepted Time:
2014-02-28 17:06:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1100682 Charles River Laboratories International Inc CRL Services-Commercial Physical & Biological Research (8731) 061397316
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1141722 C James Foster 251 Ballardvale Street
Wilmington MA 01887
Chairman, President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-02-26 1,602 $58.90 345,358 No 4 S Direct
Common Stock Disposition 2014-02-26 200 $58.91 345,158 No 4 S Direct
Common Stock Disposition 2014-02-26 200 $58.91 344,958 No 4 S Direct
Common Stock Disposition 2014-02-26 1,400 $58.91 343,558 No 4 S Direct
Common Stock Disposition 2014-02-26 100 $58.92 343,458 No 4 S Direct
Common Stock Disposition 2014-02-26 936 $58.92 342,522 No 4 S Direct
Common Stock Disposition 2014-02-26 1,302 $58.93 341,220 No 4 S Direct
Common Stock Disposition 2014-02-26 100 $58.94 341,120 No 4 S Direct
Common Stock Disposition 2014-02-26 662 $58.96 340,458 No 4 S Direct
Common Stock Disposition 2014-02-26 100 $58.97 340,358 No 4 S Direct
Common Stock Disposition 2014-02-26 100 $58.98 340,258 No 4 S Direct
Common Stock Disposition 2014-02-26 4,720 $58.78 335,538 No 4 F Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 F Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 340 Indirect By Trust
Common Stock 10,000 Indirect Held By Spouse
Footnotes
  1. This sale occured pursuant to a 10b5-1 Trading Plan.